NextCell Pharma
NextCell Pharma is a Swedish biotechnology company based in Huddinge that develops cell therapies and advanced therapy medicinal products (ATMPs) built on mesenchymal stromal cells. Its business combines a clinical-stage drug development platform with two commercial activities: Cellaviva, a stem cell banking service, and QVance, an analysis service for advanced therapies.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueClinical-stage mesenchymal stromal cell therapies, including the NXTCL/ProTrans program.
Cellaviva’s family banking service for collection and long-term storage of newborn stem cells.
QVance laboratory and analysis services for developers of advanced therapies.
Cell-based products sold for research and development use, including NextCell-Cord RUO.
Customers
NextCell sells to two main customer groups: families seeking newborn stem cell banking through Cellaviva, and life science customers involved in advanced therapy development through QVance and research-use products. Its therapeutic pipeline is aimed at patients with autoimmune and inflammatory diseases, but those programs are commercialized through partners, regulators, and clinical trial networks rather than direct patient sales.
Buy Cellaviva stem cell banking services to preserve newborn cells for possible future medical needs.
Use QVance analysis services to support development, characterization, and quality work for advanced therapies.
Purchase research-use cell products such as NextCell-Cord RUO for regenerative medicine and cell biology work.
Engage with the ProTrans/NXTCL platform for clinical development, validation, and potential commercialization.
Strategy
NextCell’s strategy is to standardize and commercialize its NXTCL cell-therapy platform while advancing the lead type 1 diabetes program toward market approval and broader indications. In parallel, it uses Cellaviva and QVance to generate operating revenue, build customer relationships in life sciences, and support the development ecosystem around advanced therapies.
The lead asset is the main value driver and validates the platform if approved.
Additional indications can broaden the addressable market and reduce single-asset dependence.
Standardized production is necessary for reproducible cell therapies and future commercialization.
Cellaviva and QVance provide nearer-term revenue and customer access while the pipeline matures.
Geography
NextCell is headquartered in Huddinge, Sweden, and its core commercial base is in Scandinavia, where Cellaviva is described as the largest private stem cell bank. The company also positions QVance around Nordic demand for advanced therapy analysis services, while its research-use products are marketed across major global markets through partners and direct sales.
Risks
NextCell faces the typical risks of clinical-stage biotech: trial outcomes may not confirm safety or efficacy, development timelines can slip, and regulatory approval is uncertain. The company also depends on key personnel, external financing, and successful commercialization of both its therapeutic pipeline and service businesses.
- Clinical development failureImpact: CriticalLikelihood: Medium
Early results may not translate into larger studies or approval, which could block commercialization.
Exposure: ProTrans/NXTCL pipeline
- Financing and dilution riskImpact: HighLikelihood: High
Development and market-building activities may require additional capital raises.
Exposure: Group-wide
- Regulatory and approval riskImpact: HighLikelihood: Medium
ATMPs require extensive evidence and regulatory clearance before market launch.
Exposure: Cell therapy programs
- Key-person dependenceImpact: MediumLikelihood: Medium
The business relies on specialized scientific, clinical, and regulatory expertise.
Exposure: Management and R&D organization
- Commercial execution riskImpact: MediumLikelihood: Medium
Cellaviva and QVance depend on customer acquisition and sustained demand in niche markets.
Exposure: Service businesses
Accounting
Judgemental itemsPrepayments for storage are recognized over time and affect revenue timing and working capital.
Impact: Cellaviva revenue and liabilities
R&D and trial costs are typically expensed as incurred, creating volatility in reported results.
Impact: Operating loss and cash burn
The company discloses an ongoing supplier dispute that may require a limited payment.
Impact: Other liabilities and expense recognition
Minority holdings such as FamicordTX may require fair value or impairment assessment.
Impact: Balance sheet and non-operating items
Similar listed companies
Publicly listed companies with a comparable business focus.
Century Therapeutics, Inc.
IPSC · Biological Products, (No Diagnostic Substances)
NextCure, Inc.
NXTC · Pharmaceutical Preparations
NewcelX Ltd.
NCEL · Pharmaceutical Preparations
Mesoblast Limited
MESO · Biological Products, (No Diagnostic Substances)
Mesoblast Ltd is a biopharmaceutical company focused on developing and commercializing allogeneic cell therapies based on mesenchymal stromal cells.
Cel-Sci Corporation
CVM · Biological Products, (No Diagnostic Substances)
BriaCell Therapeutics Corp.
BCTXZ · Pharmaceutical Preparations
Last updated: 24/09/2026